The potential employment of selective A3 adenosine receptor (A3AR) antagonists in the therapeutic treatment of important pathologies, such as asthma, inflammation, neurodegeneration, glaucoma and cancer, is subject to intensive studies because of the considerable role of this receptor in a number of pathophysiological processes. A wide number of compounds exerting high potency and selectivity in antagonizing the hA 3 AR has been so far recognized being generally characterized by a remarkable structural diversity: nitrogen-containing aromatic monocyclic (thiazoles, thiadiazoles, 1,4-dihydropyridines, pyridines, 2- mercaptopyrimidines), bicyclic (flavonoid, isoquinoline, quinozalines, (aza)adenines), tricyclic systems (pyrazoloquinolines, triazoloquinoxalines, pyrazolotriazolopyrimidines, triazolopurines, tricyclic xanthines). The latest identification of nucleoside-derived antagonists, structurally related to the endogenous ligand, opened new frontiers for the elucidation of the therapeutic potential of this kind of ligands. Probably as a result of the enigmatic physiological role of A3AR, whose activation seems related to opposite effects concerning tissues protection in inflammatory and cancer cells, a few molecules have till now reached the preclinical investigation phase. © 2010 Springer Science+Business Media B.V.

A3 adenosine receptor antagonists: History and future perspectives

Baraldi, Pier Giovanni
;
Romagnoli, Romeo;Saponaro, Giulia;Baraldi, Stefania;Tabrizi, Mojgan Aghazadeh;Preti, Delia
2010

Abstract

The potential employment of selective A3 adenosine receptor (A3AR) antagonists in the therapeutic treatment of important pathologies, such as asthma, inflammation, neurodegeneration, glaucoma and cancer, is subject to intensive studies because of the considerable role of this receptor in a number of pathophysiological processes. A wide number of compounds exerting high potency and selectivity in antagonizing the hA 3 AR has been so far recognized being generally characterized by a remarkable structural diversity: nitrogen-containing aromatic monocyclic (thiazoles, thiadiazoles, 1,4-dihydropyridines, pyridines, 2- mercaptopyrimidines), bicyclic (flavonoid, isoquinoline, quinozalines, (aza)adenines), tricyclic systems (pyrazoloquinolines, triazoloquinoxalines, pyrazolotriazolopyrimidines, triazolopurines, tricyclic xanthines). The latest identification of nucleoside-derived antagonists, structurally related to the endogenous ligand, opened new frontiers for the elucidation of the therapeutic potential of this kind of ligands. Probably as a result of the enigmatic physiological role of A3AR, whose activation seems related to opposite effects concerning tissues protection in inflammatory and cancer cells, a few molecules have till now reached the preclinical investigation phase. © 2010 Springer Science+Business Media B.V.
9789048131433
A3 adenosine receptor; A3 adenosine receptor antagonists; Adenosine; glaucoma; inflammation; Pharmacology, Toxicology and Pharmaceutics (all); Biochemistry, Genetics and Molecular Biology (all)
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2378143
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 5
social impact